Abstract:
The present invention relates to a recombinant adenovirus expressing a rabies virus gene and a vaccine composition for preventing or treating rabies comprising the same. The recombinant adenovirus according to the present invention, which is a recombinant virus of nucleotide sequences coding G protein and N protein of the rabies virus isolated from the country, effectively expresses G protein and N protein of the rabies virus and has a proliferation ability suitable for the use as a vaccine strain, and thus is suitable in mass production thereof. Further, the present invention has improved stability as compared with the exiting vaccine and thus can be used for oral administration, and has excellent ability to defend against the rabies virus at the time of vaccination.
Abstract:
The present invention relates to the recombinant rabies virus rERAG333Glu and a vaccine composition containing the same for preventing rabies. The recombinant rabies virus rERAG333Glu according to the present invention is a recombinant virus strain where the 333rd amino acid of G protein is replaced by glutamic acid. When manufacturing a vaccine from the virus, the vaccine has an excellent amount of virus so as to be suitable for mass-production, and has improved stability compared with the existing vaccines so as to be used for oral administration. Therefore, it can produce effects of solving problems of the existing rabies virus vaccines and being used as an effective vaccine for preventing rabies virus.